priors.science/reviews/sglt2-inhibitors

SGLT2 Inhibitors

The current evidence on 14 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

14claims tracked
96primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 6 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
SGLT2 inhibitors increase the risk of genital mycotic infectionsSafEstablished96%7
SGLT2 inhibitors slow kidney disease progression and reduce kidney failure riskCKDEstablished95%3
SGLT2 inhibitors reduce CV death and HF hospitalisation in HFrEFHF RefEstablished95%2
SGLT2 inhibitors reduce MACE in T2D with established cardiovascular diseaseCV T2DEstablished94%7
SGLT2 inhibitors reduce hospitalisation for heart failure in T2DCV T2DEstablished94%3
Empagliflozin reduces cardiovascular death in T2D patients with established CVDCV T2DEstablished92%7
SGLT2 inhibitors are associated with euglycaemic diabetic ketoacidosisSafEstablished87%2
SGLT2 inhibitors reduce CV death and HF hospitalisation in HFpEFHF PefLikely83%2
SGLT2 inhibitor kidney benefit extends to CKD patients without diabetesCKDLikely82%7
SGLT2 inhibitors do not significantly reduce CV mortality in HFpEFHF PefLikely79%2
SGLT2 inhibitors reduce all-cause mortality in HFrEFHF RefLikely76%4
SGLT2 inhibitors do not reduce MACE in T2D without established CVDCV T2DLikely75%1
Canagliflozin is associated with increased risk of lower limb amputationSafLikely72%7
SGLT2 inhibitor kidney benefit is greatest in patients with high albuminuriaCKDUncertain68%7
Track SGLT2 Inhibitors.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.